Moderna and Johnson & Johnson support Covid-19 vaccine boosters

The FDA panel will meet on Thursday and Friday to weigh the evidence for booster doses

Moderna vaccine
Photo: Shutterstock
Bloomberg
1 min read Last Updated : Oct 13 2021 | 1:13 AM IST
Moderna and Johnson & Johnson said that data they’ve gathered supports the need for booster shots for their Covid-19 vaccines, ahead of a key regulatory meeting later this week.

A panel of scientific experts who advise the US Food and Drug Administration on vaccines is scheduled to meet Thursday and Friday to weigh the evidence for booster doses for each of the two vaccines. The regulator has cleared a booster for the Covid shot made by Pfizer and BioNTech for those 65 and older and other at-risk adults.

The Biden administration has been pushing to make booster shots available to as many people as possible after a wave of infections over the summer tied to the delta variant. 

In addition, some studies have indicated that protection afforded by the US-authorized shots wanes over time. In documents prepared for the meeting, both companies said the supplemental doses would be advisable after six months.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusVaccineJohnson & JohnsonCoronavirus VaccineVaccination

Next Story